Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 3/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 5/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19684853 | 0.82 | TSHR (0.51) | THRATHRBKDM4EMEN1GAA | |
| SCHEMBL20107955 | 0.81 | CNR2 (0.50) | HTTRECQLSCN9APPARDPPARA | |
| SCHEMBL18021138 | 0.79 | ESR1 (0.51) | KMT2A | |
| SCHEMBL22987098 | 0.76 | SMN1; SMN2 (0.40) | HTTRECQLKDM4EMEN1KMT2A | |
| SCHEMBL12588846 | 0.76 | SCN9A (0.41) | HTTRECQLTHRATHRBSCN9A | |
| SCHEMBL20107607 | 0.76 | DHODH (0.47) | HTTRECQL | |
| SCHEMBL20107926 | 0.75 | DHODH (0.53) | HTTRECQL | |
| SCHEMBL20471959 | 0.74 | MAPT (0.37) | HTTKDM4EMEN1GAAKMT2A | |
| SCHEMBL20108206 | 0.72 | DHODH (0.49) | HTTRECQL | |
| SCHEMBL878726 | 0.71 | AAK1 (0.39) | HTTTHRATHRBSCN9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | HTT 3800/4885RECQL 1124/4885THRA 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.